跳转至内容
Merck
CN

920436

NanoFabTx PEG-PLA drug formulation screening kit

for synthesis of PEGylated nanoparticles

别名:

Microfluidics, NanoFabTx reagent kit, Nanoformulation, Nanoparticle kit, PEG-PLA

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

NACRES:
NA.23
UNSPSC Code:
12161503
Storage temp.:
2-8°C
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

description

Kit components :
PEGPLA-L-M (919942-500mg)
PEGPLA-H-M (919934-500mg)
Stabilizer-Nano (907766-5g), PEG-PLA drug formulation screening kit, for synthesis of PEGylated PLA nanoparticles

application(s)

advanced drug delivery

storage temp.

2-8°C

General description

NanoFabTx PEG-PLA drug formulation screening kit is a nanoformulation kit containing rationally selected PEGylated PLA polymers that have been used widely for controlled drug release of many different types of therapeutic molecules. The kit contains protocols for two different particle synthesis methods:
  • A Nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
  • A Microfluidics protocol using commercial platforms or syringe pumps.
The microfluidics protocol uses NanoFabTx device kits (911593), which provide all the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

Application

NanoFabTx PEG-PLA drug formulation screening kit enables users to encapsulate a wide variety of therapeutic drug molecules in specifically sized, biodegradable, PEGylated PLA nanoparticles. By simplifying the chemistry and providing an easy-to-use toolkit with step-by-step instructions, our NanoFabTx nanoformulation screening kit helps researchers achieve reproducible synthesis of drug encapsulating nanoparticles with narrow size dispersity, eliminating the need for lengthy trial-and-error optimization. Suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery, PEG-PLA nanoparticles, made using the NanoFabTx PEG-PLA drug formulation screening kit, are designed for maximizing the encapsulation of hydrophobic drugs to minimize the time and expensive wasted reagents of synthetic optimization.

Features and Benefits

  • Includes tested protocols with step-by-step instructions for nanoprecipitation or microfluidics-based syntheses
  • Requires minimal laboratory setup
  • Optimized to achieve monodisperse, homogenously shaped, biodegradable, PEGylated PLA nanoparticles in any size between 60 and 100 nm
  • Formulated to maximize the encapsulation of hydrophobic drugs
  • Includes two different PEGylated PLAs

Legal Information

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC


存储类别

10 - Combustible liquids

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


商品

Professor Robert K. Prud’homme introduces flash nanoprecipitation (FNP) for nanoparticle fabrication, which is a scalable, rapid mixing process for nanoparticle formulations.

NanoFabTX kits enable precise drug delivery with lipid nanoparticles and liposomes for mRNA and nucleic acids.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

相关内容


Solène Passemard et al.
Biomacromolecules, 18(9), 2747-2755 (2017-07-26)
The production of hydrogel microspheres (MS) for cell immobilization, maintaining the favorable properties of alginate gels but presenting enhanced performance in terms of in vivo durability and physical properties, is desirable to extend the therapeutic potential of cell transplantation. A
Xu Jia et al.
ACS biomaterials science & engineering, 2(9), 1641-1648 (2016-09-12)
Theranostic nanomedicine has recently emerged as an appealing approach for tumor chemotherapy. Here, for the first time, fluorescent carbon dots (Cdots) were used as cross-linker for tumor theranostic nanoparticles. Novel theranostic nanoparticles of approximately 27 nm with a doxorubicin (DOX)
Redouan Mahou et al.
Materials (Basel, Switzerland), 7(1), 275-286 (2014-01-09)
The progress of medical therapies, which rely on the transplantation of microencapsulated living cells, depends on the quality of the encapsulating material. Such material has to be biocompatible, and the microencapsulation process must be simple and not harm the cells.



全球贸易项目编号

货号GTIN
920436-1KT04065266037487